TrialCancer immunology, immunotherapy : CII2019

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Martin Sebastian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.